Collegium Pharmaceutical Inc (COLL)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 70,565 | 238,947 | 173,688 | 186,426 | 174,116 |
| Short-term investments | US$ in thousands | 92,198 | 71,601 | 0 | — | — |
| Total current liabilities | US$ in thousands | 509,510 | 457,915 | 270,114 | 230,399 | 191,226 |
| Cash ratio | 0.32 | 0.68 | 0.64 | 0.81 | 0.91 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($70,565K
+ $92,198K)
÷ $509,510K
= 0.32
The cash ratio of Collegium Pharmaceutical Inc has shown a declining trend over the period from December 31, 2020 to December 31, 2024. The ratio stood at 0.91 on December 31, 2020, indicating that the company had $0.91 in cash and cash equivalents for every $1 of its current liabilities. However, by December 31, 2024, the cash ratio had decreased to 0.32, suggesting a significant reduction in the company's ability to cover its short-term obligations with its available cash resources. This downward trend may raise concerns about the company's liquidity position and ability to meet its immediate financial obligations. Further investigation into the company's cash management practices and potential cash flow challenges may be warranted to address these declining ratios.
Peer comparison
Dec 31, 2024